Sage Therapeutic Com (NASDAQ:SAGE).
Baker Bros. Advisors Lp increased its investment in Sage Therapeutic Com shares by 94.6% in the quarter ending 09/30/2017. Its stake was valued at $25,262,000 an increase of $8,671,000 according to the filing.
Several firms have shifted positions in (SAGE). As of the end of the quarter Bb Biotech Ag had bought a total of 185,000 shares growing its holdings by 20.4%. The value of the total investment in Sage Therapeutic Com went from $72,268,000 to $68,059,000 a change of 5.8% quarter to quarter. Oppenheimerfunds, Inc. expanded its position by buying 8,364 shares an increase of 0.5%. Oppenheimerfunds, Inc. currently owns 1,794,004 shares valued at $111,766,000. The total value of its holdings decreased 21.4%.
Raymond James & Associates cut its ownership by selling 8,631 shares a decrease of 37.9% in the quarter. Raymond James & Associates owns 14,167 shares with a value of $883,000. The value of the position overall is down by 51.4%.
Equity analyst Needham & Company LLC raised the price target on November 10 boosting the projection from $86.00 to $100.00 and issued a “Buy” rating.
Raymond James Financial raised the price target on November 9 changing the forecast from $0.00 to $109.00 with a “Buy” recommendation. Stifel Nicolaus raised the price target of the stock on November 9 changing the price objective from $91.00 to $105.00 and stated a “Buy” rating.
Equity analyst Leerink Swann raised the price target on November 9 changing the price objective from $85.00 to $123.00 and issued a “Positive” recommendation. Royal Bank Of Canada raised the price target on November 9 changing the price objective from $0.00 to $145.00 with a rating of “Outperform”.
In the market the company is trading down by 1.58% since yesterday’s close of 88.25. The company’s P/E ratio is N/A and the market cap is 3.26B. In the last earnings report the EPS was $-6.87 with 37.54M shares currently outstanding.
Investors are a little more bullish on the company recently as inferred by the downtick in short interest. The stock saw a fall in short interest of -7.51% as of October 13, 2017 from the last reporting period. Short interest fell from 3,637,839 to 3,364,672 over that period. The days to cover increased to 8.0 and the percentage of shorted shares was 0.09% on October 13.